SPOTLIGHT -
Phase 2 Study of COMP360 Psilocybin Finds Improved PTSD Symptoms
The psilocybin did well on safety and efficacy in this phase 2 trial of patients with PTSD.
Early Career Psychiatrist Shares Thoughts on Annual Meeting
Sudhakar K. Shenoy, MD, discusses annual meeting, hot topics in child and adolescent psychiatry, and other issues in psychiatry.
Experts Shed Light on Workplace Violence in Health Care Settings
Laura T. Safar, MD, led a discussion on the prevalence and prevention of violence in the workplace.
Annual Meeting: Poster Investigates the Link Between Semaglutide and Suicidal Ideation
Poster aims to improve awareness of the potential risk of suicidal ideation in patients taking semaglutide.
Poster Finds Inflammatory Commonality Between MDD and Dermatological Diseases
Poster at the 2024 APA Annual Meeting explores link between MDD, atopic dermatitis, psoriasis, and inflammation.
Disability as the Next Step in DEI Explored at Annual Meeting
Speakers at the APA Annual Meeting share insights regarding to disability, both in patients and in clinicians.
Ingrezza Sprinkle Capsules Received FDA Approval for Tardive Dyskinesia in Adults
The new formulation was approved to help patients with tardive dyskinesia who have trouble swallowing.
Brexpiprazole + Sertraline Combination for PTSD Submitted for sNDA Review
A supplemental new drug application was submitted for the combination of brexpiprazole and sertraline in the treatment of PTSD in adults.
Landmark Study Highlights Efficacy of MDMA-Assisted Therapy for PTSD
In a first of its kind study, MDMA-assisted therapy successfully supported patients with PTSD.
Annual Conference Highlights New Research, Advances in ADHD
In an exclusive interview, APSARD President Elect Greg Mattingly, MD, tells Psychiatric Times readers what they can expect at this year's meeting.
Looking to the Future of Mood Disorders Treatment
Psychiatric Times chats with new Mood Disorders Section Editor Gus Alva, MD, about his new role, his interest in mood disorders, and his love of psychiatry.
Insights and Highlights From the Annual Psychiatric Times World CME Conference
Did you miss the 2023 Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.
Preliminary Phase 2 Data Shows Psilocybin for PTSD Is Well-Tolerated
Initial data from phase 2 safety profile for psilocybin in the treatment of PTSD indicates the treatment is well-tolerated.
Remember and Commit: 2023 World AIDS Day
2023 World AIDS Day looks to remember those who have been lost and a renewed commitment to supporting patients with HIV/AIDS.
To BD or Not to Diagnose BD: That's the Question
What are some key considerations in diagnosing bipolar disorder? Joseph F. Goldberg, MD, shares insights at the recent 2023 Annual Psychiatric Times World CME Conference.
Beyond Benzos: Treatment Options for Insomnia
What are the treatment options for insomnia when avoiding benzodiazepines? John W. Winkelman MD, PhD, shares insights and guidance at the 2023 Annual Psychiatric Times World CME Conference.
Orexin: The New Kid on the Insomnia Block
The newest class of medications to treat insomnia have many advantages.
Pioneering Change in Juvenile Correctional Psychiatry
Elizabeth Lowenhaupt, MD, CCHP, shares her insights and experiences on correctional psychiatry and juvenile mental health as she looks toward the future of the field.
FDA Approves First Oral Selective 5HT1A Receptor Agonist for MDD
Following a long path to approval, gepirone hydrochloride extended-release tablets (Exxua) is the first FDA-approved medication with this novel mechanism of action for adults with MDD.
Sleep Research Roundup: August 18
What's new in sleep research?
Phase 3 Study Finds Subcutaneous Ketamine Safe and Effective in TRD
In the largest study of its kind to date, researchers found promising results for subcutaneous ketamine for treatment resistant depression.
New Research, Treatment Issues Featured at Annual Meeting
Did you miss our APA Annual Meeting coverage?
Poster Highlights Racial/Ethnic Disparities in LAI Use
Data presents opportunities to enhance care and improve treatment adherence.
Poster Examines Accuracy of DID Information on TikTok, YouTube
Poster presented at the 2023 American Psychiatric Association Annual Meeting highlights the good and bad of social media information.
Leveraging Alliance-Based Interventions to Address Suicide Risk
Session at the 2023 Annual Meeting provides framework for addressing suicidal ideation.
Meeting Poster Explores New Onset Psychosis in COVID-19
Research explores the differences between new-onset psychosis in patients with infection versus healthy controls.
Multidisciplinary Program Improves Perinatal Depressive Symptoms
Study results presented at the 2023 American Psychiatric Association Annual Meeting.
The Importance of Evolutionary Psychiatry Explored at Annual Meeting
Leveraging evolutionary psychiatry may help clinicians and patients alike.
Addressing Narcolepsy: Approaches and Advances
MDD: Test Your Knowledge
Test your knowledge on issues in major depressive disorder.